Pharmacokinetics
Robust pharmacokinetic sampling was performed across 7 days in cycle 1, 2 days in cycle 2, and before and after CB-103 dosing in cycles 3–6. Mean pharmacokinetic plasma concentrations (ng/mL) increased across dose-escalation cohorts 1 through 8 (522 mg once daily) demonstrating a peak (t